EASD 2020: REWIND: CV Benefits of Dulaglutide on MACE Are Not Attributable to HbA1C, Weight, or Antihypertensive Effects
Potential mediators of the CV benefit of dulaglutide in the trial were explored.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.